Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 3
2009 5
2010 12
2011 5
2012 4
2013 13
2014 20
2015 13
2016 12
2017 12
2018 18
2019 28
2020 21
2021 32
2022 27
2023 24
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid.
Nohara T, Takimoto A, Shinzawa R, Kurauchi D, Toriumi R, Nakagawa R, Aoyama S, Kamijima T, Kano H, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Izumi K, Mizokami A. Nohara T, et al. Among authors: izumi k. Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15477. Online ahead of print. Int J Urol. 2024. PMID: 38687138
A seed link connector protruding into the bladder formed a bladder stone.
Aoyama S, Izumi K, Makino T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A. Aoyama S, et al. Among authors: izumi k. IJU Case Rep. 2024 Feb 9;7(2):188-191. doi: 10.1002/iju5.12704. eCollection 2024 Mar. IJU Case Rep. 2024. PMID: 38440715 Free PMC article.
Does the quality of endoscopic equipment influence the recurrence rate after photodynamic diagnosis-assisted transurethral resection of bladder tumor?
Nakagawa R, Nohara T, Kano H, Makino T, Naito R, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Izumi K, Mizokami A. Nakagawa R, et al. Among authors: izumi k. Photodiagnosis Photodyn Ther. 2024 Feb 22;46:104023. doi: 10.1016/j.pdpdt.2024.104023. Online ahead of print. Photodiagnosis Photodyn Ther. 2024. PMID: 38401816 Free article.
Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer.
Kano H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Kamijima T, Makino T, Naito R, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Nohara T, Mizokami A. Kano H, et al. Among authors: izumi k. Biomedicines. 2024 Jan 26;12(2):292. doi: 10.3390/biomedicines12020292. Biomedicines. 2024. PMID: 38397894 Free PMC article.
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Mita K, et al. Among authors: izumi k. Cancers (Basel). 2024 Jan 24;16(3):508. doi: 10.3390/cancers16030508. Cancers (Basel). 2024. PMID: 38339260 Free PMC article.
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E, Arranz JÁ, De Santis M, Bamias A, Kikuchi E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, O'Donnell PH, Kalebasty AR, Ye D, Mariathasan S, Bene-Tchaleu F, Bernhard S, Lee C, Davis ID, Galsky MD. Grande E, et al. Among authors: izumi k. Lancet Oncol. 2024 Jan;25(1):29-45. doi: 10.1016/S1470-2045(23)00540-5. Epub 2023 Dec 12. Lancet Oncol. 2024. PMID: 38101433 Clinical Trial.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Bamias A, Davis ID, Galsky MD, Arranz JÁ, Kikuchi E, Grande E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, Panni S, Gumus M, Özgüroğlu M, Mariathasan S, Poloz Y, Bene-Tchaleu F, Lee C, Bernhard S, De Santis M. Bamias A, et al. Among authors: izumi k. Lancet Oncol. 2024 Jan;25(1):46-61. doi: 10.1016/S1470-2045(23)00539-9. Epub 2023 Dec 12. Lancet Oncol. 2024. PMID: 38101431 Clinical Trial.
229 results